Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Persister Cells May Reshape Cancer Stabilization Therapy Models

A bioRxiv model examines how persister cancer cells influence treatment stability, resistance emergence, and the balance between tumor coexistence states.

By Dr. Revathy Mohan V.R., MBBS · Oct 20, 2026 · 5 min read

Oncology·Nat Rev Onc

Cincinnati Children’s seeks brain tumor research faculty for CNS malignancies

Cincinnati Children’s is recruiting faculty in brain tumor research to expand translational programs in CNS malignancies, therapies, and…

Oct 20, 2026

Oncology·Nat Rev Onc

MSK seeks postdoc in computational immuno-oncology and toxicity research

Memorial Sloan Kettering is recruiting a postdoctoral fellow to study immune-related adverse events using clinical text, genomics, and…

Oct 20, 2026

Oncology·Nat Rev Onc

MSK Opens Postdoc Role in Computational Oncology and Gastric Cancer Immunology

Memorial Sloan Kettering seeks a postdoctoral fellow to advance single-cell and spatial biology studies in gastric cancer immunology…

Oct 20, 2026

Oncology·Nat Rev Onc

TALENTOP trial: liver resection improves survival in locally advanced HCC

Phase III TALENTOP data support liver resection after atezolizumab and bevacizumab induction for selected locally advanced hepatocellular carcinoma.

Oct 20, 2026

Oncology·Nat Rev Onc

Daraxonrasib shows early activity in RAS-mutant NSCLC after prior therapy

Phase I/II data suggest daraxonrasib may have activity in previously treated RAS-mutant NSCLC, with safety as the primary…

Oct 20, 2026

Oncology·Nat Rev Onc

Tambotatug pelitecan shows promise in second-line SCLC phase III trial

Phase III TAISHAN-302 tested tambotatug pelitecan against topotecan in previously treated SCLC and found promising second-line results.

Oct 20, 2026

Oncology·Nat Rev Onc

Blinatumomab Replaces Post-Consolidation Chemotherapy in High-Risk B-ALL

Phase III AIEOP-BFM ALL 2017 data support post-consolidation blinatumomab as a chemotherapy-sparing option for children with high-risk B-ALL.

Oct 20, 2026

Oncology·Nat Rev Onc

Adjuvant Radiotherapy Improves Outcomes in Resected Atypical Meningioma

Phase III ROAM/EORTC-1308 shows adjuvant radiotherapy improves outcomes after complete resection of atypical meningioma, strengthening postoperative care.

Oct 20, 2026

Oncology·Nat Rev Onc

Daraxonrasib Approval Raises Access Questions in Metastatic Pancreatic Cancer

FDA approval of daraxonrasib for metastatic pancreatic adenocarcinoma opens access for patients unable to reach later-line therapy, despite…

Oct 20, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.